Free Delivery Over $100
|
|
|||
|
||||
OverviewThe discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst the current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research and drug discovery. The editors will combine their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery and medicinal chemistry for major psychiatric disorders, such as schizophrenia, depression, anxiety, ADHD, bipolar disorder, addiction and autism. Full Product DetailsAuthor: Zoran Rankovic , Richard Hargreaves , Matilda Bingham , David E. ThurstonPublisher: Royal Society of Chemistry Imprint: Royal Society of Chemistry Volume: 28 ISBN: 9781849734943ISBN 10: 1849734941 Pages: 678 Publication Date: 08 October 2012 Audience: Professional and scholarly , Professional & Vocational Format: Electronic book text Publisher's Status: Active Availability: Temporarily unavailable  The supplier advises that this item is temporarily unavailable. It will be ordered for you and placed on backorder. Once it does come back in stock, we will ship it out to you. Table of ContentsGeneral Editor's Preface; Preface; Acknowledgements; Contributors; Introduction. 1. Look both ways before crossing: developments in the language and literature classroom, Ronald Carter 2. Representational language learning: from language awareness to text awareness, John McRae 3. Stylistics 'upside down': using stylistic analysis in the teaching of language and literature, Mick Short 4. Designing group work activities: a case study, Alan Durant 5. Reconstructing and deconstructing: drama texts in the classroom, Michael McCarthy 6. That's for your poetry book!, Alan Maley 7. Picking holes: close procedures in prose, Anita Weston 8. Learner autonomy and literature teaching, Barbara Sinclair 9. Making the subtle difference: literature and non-literature in the classroom, Guy Cook 10. 'Interfacing' language and literature: with special reference to the teaching of British cultural studies, Mao Sihui 11. 'Viewer, I married him': literature through video, Anthony Jennings 12. Common ground; incorporating new literatures in English in language and literature teaching, Malachi Edwin Vethamani Bibliography IndexReviewsAuthor InformationZoran Rankovic is a Senior Research Fellow and a Head of Medicinal Chemistry section at MSD, Merck Research Laboratories, U.K. 15 years experience in drug discovery with a track record of delivering compounds into the development for a number of therapeutic areas, including psychiatry. Over a decade of a direct involvement in shaping the early discovery portfolio for the neuroscience franchise. Zoran has a PhD in organic chemistry from the University of Leeds, UK. Richard Hargreaves is Vice President and Worldwide Head of Neuroscience Discovery Research at Merck - completed his doctorate through the Physiology Department at King's College London University UK. Joined Merck's Neuroscience Research Center in Harlow UK in 1988. Leader of the discovery biology teams that contributed to the development of MAXALT(R) (rizatriptan) for the treatment of migraine and EMEND(R) (aprepitant) and IVEMEND(R) (fosaprepitant), novel agents that advance the protective pharmacotherapy of acute and delayed chemotherapy-induced nausea and vomiting and post-operative nausea and vomiting. In 1999 he became Vice President Worldwide Head of Imaging with the assignment to establish and lead a worldwide imaging research strategy for Merck Research Laboratories. Matilda Bingham is currently Team Leader in the Medicinal Chemistry Department, MSD; 8 years research experience in neuroscience research in a pharmaceutical setting, participating and leading teams in the neuroscience area, specialising in the transporter and GPCR target classes. Tab Content 6Author Website:Countries AvailableAll regions |
||||
